<p>輝瑞（<strong>NYSE: PFE</strong>）的股價在過去一個月上漲了 8.24%，將其年初至今的損失減少至 5.02%。在過去一年中，PFE 的股價下跌了 8.75%。最近，FDA 宣佈將僅推薦 65 歲及以上的老年人和某些醫療條件患者接種 COVID-19 疫苗，排除了健康成年人和某些年齡以上的兒童。這可能對輝瑞造成嚴重的逆風，其新冠病毒相關產品——Paxlovid 和 Comirnaty——在 2024 年貢獻了 111 億美元的總收入。</p>
<p>儘管 2024 年年末的業績強勁，輝瑞在 2025 年仍在尋找立足之地，這得益於其 COVID 產品以及非 COVID 產品（如 Vyndaquel、Padcev 和 Eliquis）的銷售超出預期。這家成立 176 年的大型製藥公司在其行業中處於領先地位。輝瑞長期以來以大規模生產抗寄生蟲藥物 santonin、青黴素和抗生素而聞名，20 世紀後期輝瑞發明了偉哥（治療勃起功能障礙）、佐洛夫（抗抑鬱藥）和立普妥（降膽固醇藥物），使公司市值達到數千億美元。</p>
<p>但在過去五年中，儘管輝瑞支付了當前收益率為 6.81% 的股息，股票仍讓股東失望。在此期間，輝瑞的股價下跌超過 31%，自 2021 年 12 月 17 日的歷史高點以來，PFE 的股價下跌超過 57%。<strong>24/7 Wall St.</strong> 進行了分析，以為潛在投資者提供對未來五年股票走勢的想法。</p>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg"/></p>
<h2>本文的關鍵點：</h2>
<ul>
<li>輝瑞預測 2025 財年的總收入將在 610 億美元至 640 億美元之間，新獲得的藥物將填補 COVID 產品（如 Paxlovid）滯後的空缺。</li>
<li>腫瘤學銷售預計將增長，約佔公司收入的 25%，有多種藥物不僅在研發中，還處於後期開發階段。</li>
<li>如果您正在尋找具有巨大潛力的重大趨勢，請確保獲取我們 <strong>“下一個 NVIDIA” 報告</strong> 的免費副本。該報告詳細分析了具有 10 倍潛力的 AI 股票，並將為您在這一重大變革中獲利提供巨大的幫助。</li>
</ul>
<h2>輝瑞近期股票成功</h2>
<p>作為一家傳統制藥公司，輝瑞是家喻户曉的名字，既是買入持有型投資組合的固定成分，也是收入型投資組合的常客。在 2024 年，公司通過股息直接向股東返還了 95 億美元。在過去 40 年中，輝瑞的股價上漲了 1139%。2014 年，輝瑞收購了 Innopharma 和 Baxter International 的疫苗組合。2016 年，它收購了 Anacor Pharmaceuticals。2019 年，公司收購了 Therachon。然而，在過去三年中，輝瑞的股價表現不佳。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>財年</strong></td>
<td><strong>價格</strong></td>
<td><strong>收入</strong></td>
<td><strong>淨收入</strong></td>
</tr>
<tr>
<td>2015</td>
<td>$30.63</td>
<td>$48.851 B</td>
<td>$6.960 B</td>
</tr>
<tr>
<td>2016</td>
<td>$30.82</td>
<td>$52.824 B</td>
<td>$7.215 B</td>
</tr>
<tr>
<td>2017</td>
<td>$34.36</td>
<td>$52.546 B</td>
<td>$21.308 B</td>
</tr>
<tr>
<td>2018</td>
<td>$41.41</td>
<td>$40.825 B</td>
<td>$11.153 B</td>
</tr>
<tr>
<td>2019</td>
<td>$37.17</td>
<td>$40.905 B</td>
<td>$16.026 B</td>
</tr>
<tr>
<td>2020</td>
<td>$36.81</td>
<td>$41.651 B</td>
<td>$9.159 B</td>
</tr>
<tr>
<td>2021</td>
<td>$59.05</td>
<td>$81.288 B</td>
<td>$21.979 B</td>
</tr>
<tr>
<td>2022</td>
<td>$51.24</td>
<td>$100.330 B</td>
<td>$31.372 B</td>
</tr>
<tr>
<td>2023</td>
<td>$28.79</td>
<td>$58.496 B</td>
<td>$2.119 B</td>
</tr>
<tr>
<td>2024</td>
<td>$26.53</td>
<td>$55.166 B</td>
<td>-$2.595 B</td>
</tr>
</tbody>
</table>
<p>在 COVID-19 出現之前的五年中，PFE 的股價上漲了 20.17%。作為疫情疫苗競賽的三大贏家之一，該股在 2021 年大幅上漲，年末時上漲了 60.41%。但自 2022 年底以來，這一效應逐漸消退，股價回落。然而，有一些順風因素可能會使輝瑞的股價在未來幾年反彈。</p>
<h2>輝瑞股票表現的關鍵驅動因素</h2>
<p><strong>1. 擺脱 COVID 的影響：</strong> 在 2024 年第四季度的財報電話會議上，首席財務官 Dave Denton 表示：“我們的收入波動性在很大程度上已經過去，因為與 COVID 相關的不確定性已經減少。” 隨着 COVID 病例持續下降，公司能夠重新聚焦（並重新分配資本支出）於一系列非 COVID 和腫瘤藥物——Denton 表示，這預計將 “為持續的利潤擴張奠定基礎。” 輝瑞正在開發多種珍貴的腫瘤藥物，該藥物市場預計將在 2025 年至 2030 年間實現 8.1% 的複合年增長率（CAGR）。此外，公司非 COVID 藥物產品在 2024 年增長了 12%，超出了 9% 至 11% 的指導範圍。</p>
<p><strong>2. 肥胖藥物需求的擴大：</strong> 儘管輝瑞在肥胖藥物領域的進入較晚，導致其將相當大的市場份額讓給了諾和諾德的 Ozempic，但輝瑞已推進其每日一次口服制劑_dangulipron_的開發。公司將肥胖視為未來的一個關鍵治療領域。肥胖藥物行業預計將在 2025 年至 2030 年間實現 22.3% 的顯著複合年增長率。</p>
<p><strong>3. 聯合營銷藥物：</strong> 輝瑞與百時美施貴寶合作，共同營銷抗凝血藥物 Eliquis。這一合作在 2024 年第四季度帶來了 18.3 億美元的收入，同比增長 14%，超出了分析師預期的 16.7 億美元。抗凝血藥物市場在 2023 年的估值為 348 億美元，預計在 2024 年至 2030 年間實現 10.2% 的複合年增長率。</p>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/01/imageForEntry4-6PZ.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/01/imageForEntry4-6PZ.jpg"/></p>
<h2>輝瑞（PFE）2025-2030 年價格預測</h2>
<p>根據分析師的共識，輝瑞當前的一年價格目標為 28.38 美元，這代表着在未來 12 個月內相較於 PFE 當前股價的 12.26% 的潛在上漲。在覆蓋輝瑞的 18 位分析師中，該股獲得了 “適度買入” 的共識評級，其中 5 位分析師給予 “買入” 評級，13 位給予 “持有” 評級，0 位給予 “賣出” 評級。</p>
<p>然而，到 2025 年底，<strong>24/7 Wall St.</strong> 的預測顯示輝瑞的股票將以 33.60 美元的價格交易，基於預計每股收益（EPS）為 2.80 美元和前瞻市盈率（P/E）為 7.53。這個價格目標相較於今天的股價有 32.91% 的潛在上漲空間。</p>
<h2>輝瑞股票價格目標到 2030 年</h2>
<p>根據我們的分析，<strong>24/7 Wall St.</strong> 預測輝瑞的股票到 2030 年底將以 34.08 美元的價格交易。這個價格目標相較於今天的股價有 34.81% 的潛在上漲空間。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>年份</strong></td>
<td><strong>價格</strong></td>
<td><strong>與當前價格的變化百分比</strong></td>
</tr>
<tr>
<td>2025</td>
<td>$33.60</td>
<td>32.91%</td>
</tr>
<tr>
<td>2026</td>
<td>$36.00</td>
<td>42.40%</td>
</tr>
<tr>
<td>2027</td>
<td>$36.72</td>
<td>45.25%</td>
</tr>
<tr>
<td>2028</td>
<td>$33.24</td>
<td>31.48%</td>
</tr>
<tr>
<td>2029</td>
<td>$32.64</td>
<td>29.11%</td>
</tr>
<tr>
<td>2030</td>
<td>$34.08</td>
<td>34.81%</td>
</tr>
</tbody>
</table>
<p>關於輝瑞公司（NYSE: PFE）2025-2030 年價格預測和展望的文章首次出現在 24/7 Wall St.上。</p>

輝瑞

<p>輝瑞公司（NYSE: PFE）在過去一個月的股價上漲了 8.24%，將其年初至今的虧損減少至 5.02%。然而，過去一年該股下跌了 8.75%。美國食品藥品監督管理局（FDA）最近的建議將 COVID-19 疫苗的接種限制在老年人和特定病症患者，這給輝瑞的 COVID 產品收入帶來了挑戰。儘管 COVID 和非 COVID 產品的銷售強勁，但該股在過去五年中下跌超過 31%。輝瑞預計 2025 財年的收入將在 610 億美元到 640 億美元之間，主要受腫瘤學銷售和新藥收購的推動</p>

<p>Shares of <strong>Pfizer (</strong> <strong>NYSE: PFE</strong> <strong>)</strong> surged 8.24% over the past month, reducing the stock’s year-to-date loss to 5.02%. Over the past year, PFE has fallen by 8.75%. Recently, the FDA announced it will only be recommending COVID-19 vaccines for seniors aged 65 and older and those with certain medical conditions, excluding healthy adults and children above a certain age from its recommendation. That may act as a severe headwind for Pfizer, whose coronavirus franchise — Paxlovid and Comirnaty — contributed $11.1 billion in combined revenue in 2024.</p>
<div class="lb-trans"><p>輝瑞（<strong>NYSE: PFE</strong>）的股價在過去一個月上漲了 8.24%，將其年初至今的損失減少至 5.02%。在過去一年中，PFE 的股價下跌了 8.75%。最近，FDA 宣佈將僅推薦 65 歲及以上的老年人和某些醫療條件患者接種 COVID-19 疫苗，排除了健康成年人和某些年齡以上的兒童。這可能對輝瑞造成嚴重的逆風，其新冠病毒相關產品——Paxlovid 和 Comirnaty——在 2024 年貢獻了 111 億美元的總收入。</p>
</div><p>Pfizer continues to search for its footing in 2025 despite strong year-end 2024 results driven by stronger-than-expected sales from its COVID products, as well as its non-COVID products, such as Vyndaquel, Padcev and Eliquis. The 176-year-old Big Pharma mainstay has been at the forefront of its industry for several decades. Long known for its mass production of santonin (an antiparasitic drug), penicillin, and antibiotics, the latter part of the 20th century saw Pfizer invent Viagra (erectile dysfunction), Zoloft (anti-depressant) and Lipitor (high cholesterol) treatments, catapulting the company to a market cap in the hundreds of billions.</p>
<div class="lb-trans"><p>儘管 2024 年年末的業績強勁，輝瑞在 2025 年仍在尋找立足之地，這得益於其 COVID 產品以及非 COVID 產品（如 Vyndaquel、Padcev 和 Eliquis）的銷售超出預期。這家成立 176 年的大型製藥公司在其行業中處於領先地位。輝瑞長期以來以大規模生產抗寄生蟲藥物 santonin、青黴素和抗生素而聞名，20 世紀後期輝瑞發明了偉哥（治療勃起功能障礙）、佐洛夫（抗抑鬱藥）和立普妥（降膽固醇藥物），使公司市值達到數千億美元。</p>
</div><p>But over the past five years, the stock has let shareholders down despite paying a dividend with a current and substantial yield of 6.81%. Over that period, Pfizer has fallen more than 31%, and since its all-time high on December 17, 2021, shares of PFE are down more than 57%. <strong>24/7 Wall St.</strong> has performed analysis to provide prospective and investors with an idea of where the stock might be headed over the course of the next five years.</p>
<div class="lb-trans"><p>但在過去五年中，儘管輝瑞支付了當前收益率為 6.81% 的股息，股票仍讓股東失望。在此期間，輝瑞的股價下跌超過 31%，自 2021 年 12 月 17 日的歷史高點以來，PFE 的股價下跌超過 57%。<strong>24/7 Wall St.</strong> 進行了分析，以為潛在投資者提供對未來五年股票走勢的想法。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2025/01/Follow-Our-500000-AI-Portfolio-3.jpg"/></p>
<h2>Key Points in This Article:</h2>
<div class="lb-trans"><h2>本文的關鍵點：</h2>
</div><ul>
<li>Pfizer forecasts FY 2025 total revenues between $61 billion and $64 billion, with newly acquired drugs filling the gap for lagging COVID products such as Paxlovid.</li>
<li>Oncology sales, which comprise around 25% of the company’s revenues, are expected to grow with several drugs not only in the pipeline but in late-stage development.</li>
<li>If you’re looking for a megatrend with massive potential, make sure to grab a complimentary copy of our <strong>“The Next NVIDIA” report</strong>. This report breaks down AI stocks with 10x potential and will give you a huge leg up on profiting from this massive sea change.</li>
</ul>
<div class="lb-trans"><ul>
<li>輝瑞預測 2025 財年的總收入將在 610 億美元至 640 億美元之間，新獲得的藥物將填補 COVID 產品（如 Paxlovid）滯後的空缺。</li>
<li>腫瘤學銷售預計將增長，約佔公司收入的 25%，有多種藥物不僅在研發中，還處於後期開發階段。</li>
<li>如果您正在尋找具有巨大潛力的重大趨勢，請確保獲取我們 <strong>“下一個 NVIDIA” 報告</strong> 的免費副本。該報告詳細分析了具有 10 倍潛力的 AI 股票，並將為您在這一重大變革中獲利提供巨大的幫助。</li>
</ul>
</div><h2>Pfizer’s Recent Stock Success</h2>
<div class="lb-trans"><h2>輝瑞近期股票成功</h2>
</div><p>As a legacy drugmaker, Pfizer is a household name and fixture in both buy-and-hold and income portfolios. In 2024, the company returned $9.5 billion directly to shareholders through dividends. Over the past 40 years, the stock has gained 1,139%. In 2014, Pfizer purchased Innopharma and Baxter International’s vaccine portfolio. In 2016, it acquire Anacor Pharmaceuticals. And in 2019, the company purchased Therachon. However, over the past three years, shares have struggled.</p>
<div class="lb-trans"><p>作為一家傳統制藥公司，輝瑞是家喻户曉的名字，既是買入持有型投資組合的固定成分，也是收入型投資組合的常客。在 2024 年，公司通過股息直接向股東返還了 95 億美元。在過去 40 年中，輝瑞的股價上漲了 1139%。2014 年，輝瑞收購了 Innopharma 和 Baxter International 的疫苗組合。2016 年，它收購了 Anacor Pharmaceuticals。2019 年，公司收購了 Therachon。然而，在過去三年中，輝瑞的股價表現不佳。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fiscal Year</strong></td>
<td><strong>Price</strong></td>
<td><strong>Revenues</strong></td>
<td><strong>Net Income</strong></td>
</tr>
<tr>
<td>2015</td>
<td>$30.63</td>
<td>$48.851 B</td>
<td>$6.960 B</td>
</tr>
<tr>
<td>2016</td>
<td>$30.82</td>
<td>$52.824 B</td>
<td>$7.215 B</td>
</tr>
<tr>
<td>2017</td>
<td>$34.36</td>
<td>$52.546 B</td>
<td>$21.308 B</td>
</tr>
<tr>
<td>2018</td>
<td>$41.41</td>
<td>$40.825 B</td>
<td>$11.153 B</td>
</tr>
<tr>
<td>2019</td>
<td>$37.17</td>
<td>$40.905 B</td>
<td>$16.026 B</td>
</tr>
<tr>
<td>2020</td>
<td>$36.81</td>
<td>$41.651 B</td>
<td>$9.159 B</td>
</tr>
<tr>
<td>2021</td>
<td>$59.05</td>
<td>$81.288 B</td>
<td>$21.979 B</td>
</tr>
<tr>
<td>2022</td>
<td>$51.24</td>
<td>$100.330 B</td>
<td>$31.372 B</td>
</tr>
<tr>
<td>2023</td>
<td>$28.79</td>
<td>$58.496 B</td>
<td>$2.119 B</td>
</tr>
<tr>
<td>2024</td>
<td>$26.53</td>
<td>$55.166 B</td>
<td>-$2.595 B</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>財年</strong></td>
<td><strong>價格</strong></td>
<td><strong>收入</strong></td>
<td><strong>淨收入</strong></td>
</tr>
<tr>
<td>2015</td>
<td>$30.63</td>
<td>$48.851 B</td>
<td>$6.960 B</td>
</tr>
<tr>
<td>2016</td>
<td>$30.82</td>
<td>$52.824 B</td>
<td>$7.215 B</td>
</tr>
<tr>
<td>2017</td>
<td>$34.36</td>
<td>$52.546 B</td>
<td>$21.308 B</td>
</tr>
<tr>
<td>2018</td>
<td>$41.41</td>
<td>$40.825 B</td>
<td>$11.153 B</td>
</tr>
<tr>
<td>2019</td>
<td>$37.17</td>
<td>$40.905 B</td>
<td>$16.026 B</td>
</tr>
<tr>
<td>2020</td>
<td>$36.81</td>
<td>$41.651 B</td>
<td>$9.159 B</td>
</tr>
<tr>
<td>2021</td>
<td>$59.05</td>
<td>$81.288 B</td>
<td>$21.979 B</td>
</tr>
<tr>
<td>2022</td>
<td>$51.24</td>
<td>$100.330 B</td>
<td>$31.372 B</td>
</tr>
<tr>
<td>2023</td>
<td>$28.79</td>
<td>$58.496 B</td>
<td>$2.119 B</td>
</tr>
<tr>
<td>2024</td>
<td>$26.53</td>
<td>$55.166 B</td>
<td>-$2.595 B</td>
</tr>
</tbody>
</table>
</div><p>Shares of PFE gained 20.17% in the five years leading up to the emergence of COVID-19. As one of the big three winners of the pandemic’s vaccine race, the stock took a big step forward in 2021, ending the year with a 60.41% gain. But since the end of 2022, that effect has faded and shares have come back down to Earth. However, there are some tailwinds that could see Pfizer’s stock rebound over the next several years.</p>
<div class="lb-trans"><p>在 COVID-19 出現之前的五年中，PFE 的股價上漲了 20.17%。作為疫情疫苗競賽的三大贏家之一，該股在 2021 年大幅上漲，年末時上漲了 60.41%。但自 2022 年底以來，這一效應逐漸消退，股價回落。然而，有一些順風因素可能會使輝瑞的股價在未來幾年反彈。</p>
</div><h2>Key Drivers of Pfizer’s Stock Performance</h2>
<div class="lb-trans"><h2>輝瑞股票表現的關鍵驅動因素</h2>
</div><p><strong>1. Moving on From COVID:</strong> During its Q4 2024 earnings call, CFO Dave Denton said “our revenue volatility is largely int he past as COVID-related uncertainties have diminished.” With COVID cases continuing to plummet, the company is able to refocus (and reallocate CapEx) towards a suite of non-COVID and oncological drugs — something Denton says is expected to “set the stage for ongoing margin expansion.” Pfizer has a number of precious oncology drugs in development, and that facet of the drug market is expected to undergo an 8.1% compound annual growth rate (CAGR) from 2025 to 2030. Additionally, the company’s non-COVID drug products rose 12% in 2024, exceeding guidance of 9% to 11%.</p>
<div class="lb-trans"><p><strong>1. 擺脱 COVID 的影響：</strong> 在 2024 年第四季度的財報電話會議上，首席財務官 Dave Denton 表示：“我們的收入波動性在很大程度上已經過去，因為與 COVID 相關的不確定性已經減少。” 隨着 COVID 病例持續下降，公司能夠重新聚焦（並重新分配資本支出）於一系列非 COVID 和腫瘤藥物——Denton 表示，這預計將 “為持續的利潤擴張奠定基礎。” 輝瑞正在開發多種珍貴的腫瘤藥物，該藥物市場預計將在 2025 年至 2030 年間實現 8.1% 的複合年增長率（CAGR）。此外，公司非 COVID 藥物產品在 2024 年增長了 12%，超出了 9% 至 11% 的指導範圍。</p>
</div><p><strong>2. Expanding Demand for Obesity Drugs:</strong> Despite its late entry in the obesity drug arena, which resulted in Pfizer ceding considerable market share to Novo Nordisk’s Ozempic, Pfizer has advanced the development of its once-daily oral formulation, <em>dangulipron</em>. The company has referred to obesity as a key therapeutic area going forward. The obesity drug industry is forecast to expand at a considerable 22.3% CAGR from 2025 to 2030.</p>
<div class="lb-trans"><p><strong>2. 肥胖藥物需求的擴大：</strong> 儘管輝瑞在肥胖藥物領域的進入較晚，導致其將相當大的市場份額讓給了諾和諾德的 Ozempic，但輝瑞已推進其每日一次口服制劑_dangulipron_的開發。公司將肥胖視為未來的一個關鍵治療領域。肥胖藥物行業預計將在 2025 年至 2030 年間實現 22.3% 的顯著複合年增長率。</p>
</div><p><strong>3. Co-Marketed Drugs:</strong> Pfizer has teamed up with Bristol Myers Squibb, with which it co-markets the blood thinner Eliquis. That endeavor resulted in $1.83 billion in Q4 2024 alone, which marked a 14% year-over-year gain for the drug, and exceeded the $1.67 billion analysts were expecting. The anticoagulant market was valued at $34.8 billion in 2023 and is forecast to undergo a 10.2% CAGR from 2024 to 2030.</p>
<div class="lb-trans"><p><strong>3. 聯合營銷藥物：</strong> 輝瑞與百時美施貴寶合作，共同營銷抗凝血藥物 Eliquis。這一合作在 2024 年第四季度帶來了 18.3 億美元的收入，同比增長 14%，超出了分析師預期的 16.7 億美元。抗凝血藥物市場在 2023 年的估值為 348 億美元，預計在 2024 年至 2030 年間實現 10.2% 的複合年增長率。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/01/imageForEntry4-6PZ.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/01/imageForEntry4-6PZ.jpg"/></p>
<h2>Pfizer (PFE) Price Prediction 2025–2030</h2>
<div class="lb-trans"><h2>輝瑞（PFE）2025-2030 年價格預測</h2>
</div><p>The current consensus one-year price target for Pfizer, according to analysts, is $28.38, which represents 12.26% potential upside over the next 12 months based on PFE’s current share price. Of the 18 analysts covering Pfizer, the stock receives a consensus “Moderate Buy” rating, with five analysts assigning it as a “Buy,” 13 assigning it as a “Hold” and zero assigning it as a “Sell.”</p>
<div class="lb-trans"><p>根據分析師的共識，輝瑞當前的一年價格目標為 28.38 美元，這代表着在未來 12 個月內相較於 PFE 當前股價的 12.26% 的潛在上漲。在覆蓋輝瑞的 18 位分析師中，該股獲得了 “適度買入” 的共識評級，其中 5 位分析師給予 “買入” 評級，13 位給予 “持有” 評級，0 位給予 “賣出” 評級。</p>
</div><p>However, by the end of 2025, <strong>24/7 Wall St.</strong>‘s forecast projects shares of Pfizer to be trading for $33.60 based on a projected EPS of $2.80 and a forward price-to-earnings (P/E) ratio of 7.53. That price target represents 32.91% potential upside from today’s share price.</p>
<div class="lb-trans"><p>然而，到 2025 年底，<strong>24/7 Wall St.</strong> 的預測顯示輝瑞的股票將以 33.60 美元的價格交易，基於預計每股收益（EPS）為 2.80 美元和前瞻市盈率（P/E）為 7.53。這個價格目標相較於今天的股價有 32.91% 的潛在上漲空間。</p>
</div><h2>Pfizer Stock Price Target for 2030</h2>
<div class="lb-trans"><h2>輝瑞股票價格目標到 2030 年</h2>
</div><p>Based on our analysis, <strong>24/7 Wall St.</strong> projects shares of Pfizer to be trading for $34.08 by the end of 2030. That price target is good for 34.81% potential upside from the stock’s price today.</p>
<div class="lb-trans"><p>根據我們的分析，<strong>24/7 Wall St.</strong> 預測輝瑞的股票到 2030 年底將以 34.08 美元的價格交易。這個價格目標相較於今天的股價有 34.81% 的潛在上漲空間。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year</strong></td>
<td><strong>Price</strong></td>
<td><strong>%Change From Current Price</strong></td>
</tr>
<tr>
<td>2025</td>
<td>$33.60</td>
<td>32.91%</td>
</tr>
<tr>
<td>2026</td>
<td>$36.00</td>
<td>42.40%</td>
</tr>
<tr>
<td>2027</td>
<td>$36.72</td>
<td>45.25%</td>
</tr>
<tr>
<td>2028</td>
<td>$33.24</td>
<td>31.48%</td>
</tr>
<tr>
<td>2029</td>
<td>$32.64</td>
<td>29.11%</td>
</tr>
<tr>
<td>2030</td>
<td>$34.08</td>
<td>34.81%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>年份</strong></td>
<td><strong>價格</strong></td>
<td><strong>與當前價格的變化百分比</strong></td>
</tr>
<tr>
<td>2025</td>
<td>$33.60</td>
<td>32.91%</td>
</tr>
<tr>
<td>2026</td>
<td>$36.00</td>
<td>42.40%</td>
</tr>
<tr>
<td>2027</td>
<td>$36.72</td>
<td>45.25%</td>
</tr>
<tr>
<td>2028</td>
<td>$33.24</td>
<td>31.48%</td>
</tr>
<tr>
<td>2029</td>
<td>$32.64</td>
<td>29.11%</td>
</tr>
<tr>
<td>2030</td>
<td>$34.08</td>
<td>34.81%</td>
</tr>
</tbody>
</table>
</div><p>The post Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025) appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>關於輝瑞公司（NYSE: PFE）2025-2030 年價格預測和展望的文章首次出現在 24/7 Wall St.上。</p>
</div>

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)

- 輝瑞公司股價在過去一個月上漲 8.24%，年初至今損失降至 5.02%。  
- FDA 僅推薦 65 歲及以上老年人接種 COVID-19 疫苗，可能對輝瑞造成壓力。  
- 分析師預計輝瑞 2025 年股價將達到 $33.60，潛在上漲 32.91%。

輝瑞公司（NYSE 代碼：PFE）2025-2030 年價格預測及展望（2025 年 7 月）